๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumor agent

Book ID
117659504
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
135 KB
Volume
38
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I Clinical and Pharmacokinetic Stu
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
โœ Strumberg, D. ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› American Society of Clinical Oncology ๐ŸŒ English โš– 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.